Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors
about
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsA Novel Class of meso-Tetrakis-Porphyrin Derivatives Exhibits Potent Activities against Hepatitis C Virus Genotype 1b Replicons In VitroTherapeutic implications of hepatitis C virus resistance to antiviral drugs.Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase.Hepatitis C virus virology and new treatment targets.Antiviral drugs against hepatitis C virus.Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants.Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection.Hepatitis C virus RNA replication and virus particle assembly require specific dimerization of the NS4A protein transmembrane domain.Antiviral therapy for hepatitis C virus: beyond the standard of care.Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.ACH-806, an NS4A antagonist, inhibits hepatitis C virus replication by altering the composition of viral replication complexesGenotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.Screening of hepatitis C virus inhibitors using genotype 1a HCV replicon cell lines.Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.Structural and functional parameters of the flaviviral protease: a promising antiviral drug target.Studies on hepatitis C virus resistance to inhibitors in replicon systems.The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China.
P2860
Q27487949-580A43F3-8F40-43F1-B5C7-621AF4243B61Q27490546-C0641671-D4EC-492F-BD07-F7723DD54CD8Q34409020-03A4ED8D-1840-4DA6-9610-D07389364616Q34620091-406DD9D3-DF07-4697-BF26-8EE3731C4B18Q34974042-1D6AE4B2-A995-4DF7-9106-5AE6D7D6B6CFQ35105567-09884CC4-36BB-4D66-917D-67B15726CC98Q36882471-737487BA-A910-4501-B5B7-2CE9932B5151Q37335699-89676F1F-70A9-4128-A93F-C34E9BBF8C8FQ37481292-0CA3A6A2-0499-4096-8B1E-C586A76C7418Q37547774-01903132-C65A-458F-9D43-46C2B21EA75DQ37945201-FCCEE2F8-467D-49F9-B372-E15703A89D7CQ38283239-3C7AC908-C2EE-42E2-A2A4-3FBF11C869B5Q39158465-7F587339-4CB0-49CD-982C-518545E00250Q39376758-5F59BD00-A9C1-4441-9EB2-B4BC8DD0376FQ39497196-5270621B-6682-4B93-8021-FE233521D94EQ39653573-822F656F-D3BA-4E5A-B00C-CAF3A29C802BQ39705689-F84BA213-AA8D-4F91-A87C-B02703195844Q39817292-B0750CEE-F60C-4BDA-B6B3-EB416613785BQ42977247-251B03B6-469F-4139-971D-94846B179873Q42991856-FB4184F2-8F11-4203-A97E-8E3DC8F243B0Q45324124-FFB6B77F-639C-4DB3-97DE-FFD4C29F7FB2
P2860
Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Selection of Replicon Variants ...... and NS5B Polymerase Inhibitors
@ast
Selection of Replicon Variants ...... and NS5B Polymerase Inhibitors
@en
Selection of Replicon Variants ...... and NS5B Polymerase Inhibitors
@nl
type
label
Selection of Replicon Variants ...... and NS5B Polymerase Inhibitors
@ast
Selection of Replicon Variants ...... and NS5B Polymerase Inhibitors
@en
Selection of Replicon Variants ...... and NS5B Polymerase Inhibitors
@nl
prefLabel
Selection of Replicon Variants ...... and NS5B Polymerase Inhibitors
@ast
Selection of Replicon Variants ...... and NS5B Polymerase Inhibitors
@en
Selection of Replicon Variants ...... and NS5B Polymerase Inhibitors
@nl
P2093
P2860
P356
P1476
Selection of Replicon Variants ...... and NS5B Polymerase Inhibitors
@en
P2093
Amy Sanchez
Atul Agarwal
Avinash Phadke
Joanne Fabrycki
Milind Deshpande
Mingjun Huang
Wengang Yang
Xiaohong Hou
Xingtie Nie
Yongsen Zhao
P2860
P304
P356
10.1128/AAC.01548-07
P407
P577
2008-06-01T00:00:00Z